The Cystic Fibrosis Gene by Smith, SJ Louise
 Res Medica, Vol II, No. 1, 1991             Page 1 of 5 
Smith, S.J.L. The Cystic Fibrosis Gene, Res Medica, Vol II, No. 1, 1991, pp.8-11           doi: 10.2218/resmedica.v2i1.956 
 
 
 
 
 
The Cystic Fibrosis Gene 
 
 
S.J. Louise Smith 
 
 
Abstract It’s now well over a year since the cystic fibrosis gene was cloned and there is still much to be done before its localisation can be translated into an improvement in health care for affected people. I’m not going to go into any details on how the gene was located, for this information (which is rather technical) see ref. 1. However to put it rather bluntly, despite the fact that the gene has been localised and sequenced has been sequenced, no-one really knows what it does. The cystic fibrosis gene has been named the CFTR gene (cystic fibrosis transmembrane conductance regulator). It is located on the long arm of chromosome 7 and is composed of 27 extrons which code for 1,400 amino-acid residues. There seem to be several different final products of the CFTR gene which result from the removal of exons from the first nucleotide binding fold. The functional significance of these products is not known.                    Copyright Royal Medical Society. All rights reserved. The copyright is retained by the author and the Royal Medical Society, except where explicitly otherwise stated. Scans have been produced by the Digital Imaging Unit at Edinburgh University Library. Res Medica is supported by the University of Edinburgh’s Journal Hosting Service: http://journals.ed.ac.uk   ISSN: 2051-7580 (Online)   ISSN: 0482-3206 (Print)     
Res Medica is published by the Royal Medical Society, 5/5 Bristo Square, Edinburgh, EH8 9AL  
Res Medica, Vol II, No. 1, 1991: 8-11 doi: 10.2218/resmedica.v2i1.956 
ARTICLE
f >
Table III. Advantages and Disadvantages o f amniocentesis 
Advantages
•  All pregnancies with a 1 in 4 risk of cystic fibrosis can be assessed.
•  No prior family workup is required
•  Assays may be completed within 1 hour of receipt of the sample 
Disadvantages
•  Decreased accuracy of diagnosis (cf.CVS). Increased false positives and 
false negatives
•  If termination is required then it will have to be a late termination 
(18-19 weeks).
major complication of advanced cystic fi­
brosis. Initially patients had a poor re­
sponse to transplantation but success rates 
are now improving. There have been no 
reports of the epithelial transport defects 
occurring in the new lung, although the 
defects are still present above the site of the 
anastamosis.
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It’s now well over a year since the cystic 
fibrosis gene was cloned and there is still 
much to be done before its localisation can 
be translated into an improvement in health 
care for affected people. I’m not going to 
go into any details on how the gene was 
located, for this information (which is 
rather technical) see ref. 1. However to put 
it rather bluntly, despite the fact that the 
gene has been localised and sequenced has 
been sequenced, no-one really knows what
it does. The cystic fibrosis gene has been 
named the CFTR gene (cystic fibrosis 
transmembrane conductance regulator). It 
is located on the long arm of chromosome 7 
and is composed of 27 extrons which code 
for 1,400 amino-acid residues. There seem 
to be several different final products of the 
CFTR gene which result from the removal 
of exons from the first nucleotide binding 
fold. The functional significance of these 
products is not known.
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Fig.1. Schematic model o f the Cystic Fibrosis gene product (CFTR). TM =Transmembrane 
region. NBF -nucleotide binding folds.
As I have already stated, the actual pro­
tein, and its function in man, is not known, 
however the sequence of the amino-acids 
forming the gene is known and this can be 
used, (directly and in comparison to other 
genes) to predict a structure for the protein. 
Using this information it is thought that the 
gene codes for a large trans-membrane 
protein which is very similar to several 
transport proteins all of which have in 
common the coupling of ATP hydrolysis to 
the pumping of molecule into or out of the 
cell. A basic diagram of the suggested 
structure is shown (Fig.l). These findings 
agree with what was already known about 
the pathogenesis of cystic fibrosis; that is 
that the disease seemed to be caused by de­
fective transport of chloride ions across epi- 
thelia. Unfortunately the story is not that 
simple, it is thought that the CFTR gene 
product is not the ion-channel involved. 
There are several reasons for this;
1) The CFTR-protein is coupled to ATP- 
hydrolysis whereas the normal ion channels 
are not.
2) Normal ion channels allow ions to flow 
across them in both directions while the 
CFTR-protein has already been shown to be 
very like a family of transport proteins 
which only allow active transport in one 
direction.
3) Chloride channels seem to be different in 
different tissues but the mutations found in 
all C . F. patients so far have been defects in 
a single gene.
4) The CFTR-protein seems to, quite sim­
ply, be too big to be a ion channel.
So, what does the protein actually do? It 
has been suggested that the protein might 
transport a molecule which regulates the 
chloride channel; another explanation is 
that the protein handles a substrate which
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Cystic Fibrosis mutations
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Fig2 . The CFTR gene exons. Each symbol shows the location of one identified mutation.
acts as a regulator on the chloride channel*2*. 
No doubt more information will be discov­
ered in the near future since this question 
seems to be central to the whole field of 
cystic fibrosis.
The finding of the CFTR gene has meant 
that the exact location of this protein in the 
tissues of the body can now be determined. 
This has been done by raising antibodies to 
the CFTR protein and examining where 
these antibodies attach to tissues. Prelimi­
nary results show that the antibodies attach 
to sweat glands and to a subset of T-cells but 
not, as would be expected bearing in mind 
the clincal observations, to the pancreatic 
cells. Furthermore it is thought that the 
antibodies bind specifically to the reabsorp- 
tive and not the secretory side of the sweat 
glands. Further studies are, of course,
needed to confirm the exact location of 
CFTR and these surprising results need to 
be explained with respect to the clinical 
disease.
A lot of work has been going on all over 
the world in an attempt to explain what has 
gone wrong with the CFTR gene in patients 
with cystic fibrosis; in others words the 
identification of the mutations in the gene. 
This has been found to be more complicated 
than would have been wished, at present 
well over 60 different mutations have been 
found in the gene. The most common of 
these is the deletion of a phenylalanine resi­
due in about 70% of all patients. In Scot­
land this is the most common mutation also, 
and accounts for about 73% of the muta­
tions in this group of patients; the next two 
commonest mutations between them acount
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for a further 11.4% of patients. These two 
mutations both involve a glycine residue, in 
the first instance glycine is changed to an 
aspartine residue, in the second mutation 
the code for glycine is changed to a “STOP” 
code which terminates the synthesis of the 
protein. The information on all mutations 
when it is collected together shows a rather 
unusual pattern: it seems the the largest 
number of mutations are clustered together 
in the area of the first nuclear binding fold 
(NBF1). (Fig.2.) The reason for this, again, 
is not really known but the second NBF has 
cetainly been examined for mutations ex- 
haustively. It has also been observed that 
there are no large deletions or rearrange­
ments anywhere in the gene which is sur­
prising given that the CFTR gene is very 
large.
Attempts have been made to match the 
muations in the gene (remember that it is a 
recessive disorder so there are two mutant 
copies) to the observed clinical situation in 
the patient, for example the most common 
mutation described as a “severe” mutation 
while other mutations found in the exons 
1,9 and 12 are “mild”. Surprisingly two 
patients with both genes containing the 
common and severe mutation have been 
found to have pancreatic sufficiency which 
confounds the above hypothesis. Such at­
tempts to match the patient's symptoms to 
the genetic cause of the disease will proba­
bly only be successful once the molecular 
basis of the disease is actually understood.
All that I've written so far seems rather 
negative however some progress has been 
made; one of the most exciting develop­
ments in the last year has been the sucess of 
correcting abnormal chloride channel per­
meability in cultured CF cell by getting 
them to express normal CFTR (3>. This
sounds promising but it must be remem­
bered that there is a huge jump from gene 
insertion into the genome of a cultured cell 
in vitro to possible gene therapy in patients 
with cystic fibrosis. This is the situation in 
all aspects of gene therapy, for all different 
diseases despite the optimism of many 
people. It has been suggested that it could 
be possible to deliver a normal CFTR gene 
to the airway epithelial cells by use of an 
aerosol delivery, this kind of treatment 
depends on the use of retroviruses to get the 
new gene inserted into the patient’s DNA. 
These techniques of retroviral therapy in- 
vivo are sadly not yet adequately devel­
oped, but who knows what will happen in 
the future?
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